Vincent van der Wel is the Director of Orfenix, which specialises in developing medicines that originate in academic research, ensuring they reach patients at an accessible price while maintaining sustainable returns for investors. By combining academic expertise with regulatory and clinical development know-how, Orfenix builds strong, collaborative partnerships between academia and industry. With a background in Medicine (Leiden University) and Health Economics (Erasmus University), Vincent has built a career focused on connecting research and practice. He has established five academic-industry collaborations, four of which work on repurposing medicines, and is an active collaborator with Rare-NL, the Dutch expert group for rare diseases and repurposing. Vincent is also a co-author of the socially responsible licensing guideline in the Netherlands and has contributed to academic publications on public-private partnerships. Committed to collaboration and patient access, Vincent believes that public-private partnerships can offer a sustainable way to bring repurposed medicines to those who need them most.
